The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaImproved survival with vemurafenib in melanoma with BRAF V600E mutationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsPrecision medicine for cancer with next-generation functional diagnosticsMelanoma: new insights and new therapiesPathways and therapeutic targets in melanomaSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyLandscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentPharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Elucidating distinct roles for NF1 in melanomagenesisPhase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaImatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinVemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.Improved overall survival in melanoma with combined dabrafenib and trametinib.Inhibition of Mutated, Activated BRAF in Metastatic MelanomaExpression of drug targets in patients treated with sorafenib, carboplatin and paclitaxelMelanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015A melanoma molecular disease modelThe state of melanoma: challenges and opportunitiesIt is time to include patients with brain tumors in phase I trials in oncologyFactors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer.Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors.Phase I trial of combretastatin a-4 phosphate with carboplatin.Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibIpilimumab for patients with advanced mucosal melanoma.Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.Isolation and molecular characterization of circulating melanoma cellsMeeting report: The future of preclinical mouse models in melanoma treatment is now.
P50
Q21133611-21FB30E4-6BC7-4798-87E6-DD82495DA3C3Q24594790-0260763B-3BB6-463D-8058-11F39EFCA4F1Q24597152-241D792D-932F-4C17-AB15-163E24814B4EQ24631953-F8D2A135-C056-4609-8542-1C48D8A5EEEAQ24632064-A2C09FF4-B006-4984-AC40-8A71F3ACAFE8Q26780232-78701B08-081D-436D-A7D9-4989E20477C7Q26853127-84064B7D-D6CC-47EE-87F1-A975436E4D8FQ26865736-DAE5C344-5BCE-45E6-9CCE-1F52CA574AB8Q27276774-FDE61D79-9ECF-4422-A2AB-0C6B3A651ED0Q27313653-95EFB200-A2A6-4B9C-8CF3-C34D4E81EC72Q27777363-522C5331-85A3-48B4-AD2A-0F3ACBF1CB8CQ27851656-0048DE4E-B1B9-4A77-B39E-D74B51FD5641Q27851852-02D41F20-E21A-48F1-91D4-7AE059A08034Q27851856-A8875EBA-1113-4FCF-82E1-C06F72D0218DQ27851952-E9A03C4A-8113-4FFB-A189-2DE51B5C3B76Q27851979-5B5E1A97-CD1E-4A82-8777-CBF85C02B4A7Q27852360-6E3D40A2-ECAB-4D54-8783-DAC7A2EA8C3CQ27852401-F22F64A5-647B-4D0D-9B81-A79B423AFBD8Q27853091-0367C57F-6E47-4FFB-84FF-E12F3C45E6B6Q27860458-153971EC-023E-4EF6-81A2-B34E98F45BDBQ28535159-B538958D-C9E6-4A43-9D75-A030DBDA0C61Q28553228-488AECD9-56AF-49BD-96CE-B54DA0A34012Q28741507-255BBE40-68F6-4D77-A686-13EDF20AEDE2Q30276971-EE4087CF-65E5-4CDC-B6BF-AF371B15D605Q30359570-015306F6-6E10-42A2-A115-7E3AB8B24C71Q31143336-7857A8C1-107C-4A11-8CE8-4C97553CB2CCQ33347295-388B7B40-0138-4C59-BC16-8072F41B9AD2Q33348574-A867568D-0FE8-4126-958A-08C1A9F9E501Q33358544-85788158-BCA1-4E3B-AE69-2519B1DC2502Q33360700-41DF5D45-3732-423A-8034-105FAD2C3FF5Q33364999-2AEB6ADE-3F83-4B9F-A976-7EA250F39941Q33365241-CB200CF6-6207-4D5F-9AE4-080F35915BE3Q33404877-7AB5584C-EA7D-4AF4-8478-C9110C93447DQ33665758-5DD54F59-A178-4252-909C-2C9140902E71Q33688428-69D3D9AB-5C29-497E-BCB4-2F7EA8B743E0Q33758211-9D0AB1E9-C44A-42B8-BCA4-4E9ECB596C81Q33777469-3C3A3E21-9365-4F92-91E7-36BA492DBF5BQ33830911-0E27DA3F-D77E-4176-9A0D-4C64059B0B0BQ33835938-4F658EE8-31D2-4781-B4C5-2277B1C7CCD0Q33945949-4D0229CB-448A-46FF-9CA1-77C1AC6A6B00
P50
description
American medical researcher
@en
name
Keith Flaherty
@ast
Keith Flaherty
@ca
Keith Flaherty
@de
Keith Flaherty
@en
Keith Flaherty
@es
Keith Flaherty
@fr
Keith Flaherty
@it
Keith Flaherty
@nl
Keith Flaherty
@sl
type
label
Keith Flaherty
@ast
Keith Flaherty
@ca
Keith Flaherty
@de
Keith Flaherty
@en
Keith Flaherty
@es
Keith Flaherty
@fr
Keith Flaherty
@it
Keith Flaherty
@nl
Keith Flaherty
@sl
prefLabel
Keith Flaherty
@ast
Keith Flaherty
@ca
Keith Flaherty
@de
Keith Flaherty
@en
Keith Flaherty
@es
Keith Flaherty
@fr
Keith Flaherty
@it
Keith Flaherty
@nl
Keith Flaherty
@sl